Vectibix
Authorised
This medicine is authorised for use in the European Union
panitumumab
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Vectibix is a medicine for treating colorectal (bowel) cancer that has spread to other parts of the body. Vectibix is used alone or with other cancer medicines in patients with a type of tumour that has normal
(‘wild-type’) copies of a gene known as RAS.
It contains the active substance panitumumab.
Vectibix can only be obtained with a prescription. Treatment with Vectibix should be supervised by a doctor who has experience in the use of cancer therapy. It should only be started after the presence of wild-type RAS has been confirmed by an experienced laboratory using a validated test method.
Vectibix is available for infusion (drip) into a vein. The recommended dose of Vectibix is 6 mg per kilogram body weight given once every two weeks. The usual recommended infusion time is approximately 60 minutes. The dose may need to be modified if severe skin reactions occur and treatment stopped if the reaction does not get better.
For more information about using Vectibix, see the package leaflet or contact your doctor or pharmacist.
The active substance in Vectibix, panitumumab, is a monoclonal antibody, a type of protein that has been designed to attach to and block a target called EGFR on certain cells, including some tumour cells. As a result, these tumour cells can no longer receive the messages transmitted via EGFR that they need to grow and spread to other parts of the body.
Panitumumab does not seem to work against tumour cells that contain mutated (abnormal) RAS genes. This is because growth of these types of cells does not depend on EGFR and they can continue to grow uncontrollably even when EGFR is blocked.
Several bowel cancer studies have shown that Vectibix is effective at prolonging life or slowing disease progression in patients with ‘wild-type’ RAS tumours that have spread. The studies show Vectibix can be effective when used alone and together with the standard chemotherapy regimens FOLFOX (a combination of fluorouracil with folinic acid and the cancer medicine oxaliplatin) or FOLFIRI (fluorouracil with folinic acid and a different cancer medicine, irinotecan).
Here are some of the main results from these studies:
- Patients receiving Vectibix in combination with FOLFOX lived for an average of 10.1 months without the disease getting worse in a study of 1,183 previously untreated patients compared with 7.9 months for those receiving FOLFOX alone.
- Around 59% of patients who received Vectibix plus FOLFIRI in a study of 154 previously untreated had some reduction in signs of cancer. Patients in this study (there was no comparator treatment) lived for an average of 11.2 months without their disease getting worse.
- Around 73% of patients given Vectibix plus FOLFIRI and 78% of those given Vectibix with FOLFOX had some reduction in signs of cancer in a study of 80 previously untreated patients. Patients given these combinations lived for an average of 14.8 months and 12.8 months respectively without their disease getting worse.
- Patients given Vectibix in combination with FOLFIRI lived for 16.2 months in a study of 1,186 previously treated patients compared with 13.9 months in patients receiving FOLFIRI alone. Patients receiving Vectibix also had a longer period of time without their disease getting worse: 6.4 months versus 4.6 months.
- Patients with wild-type tumours who received Vectibix alone had no disease progression for an average of 16 weeks in a study of 463 patients, compared with 8 weeks in those who did not receive Vectibix and only had supportive care. This study involved patients with either wild-type or mutant RAS whose disease had got worse despite treatments that included a fluoropyrimidine, oxaliplatin and irinotecan. It was later confirmed that benefit is limited only to patients with wild- type RAS tumours.
In studies, 93% of the patients receiving Vectibix had side effects affecting the skin, although most of these were mild or moderate. The most common side effects with Vectibix (in more than 2 patients in 10) were diarrhoea, nausea (feeling sick), vomiting, constipation, abdominal pain (stomach ache), tiredness, fever, lack of appetite, paronychia (nail bed infection), rash, acneiform dermatitis (skin inflammation resembling acne), pruritus (itching), erythema (reddening of the skin) and dry skin. For the full list of side effects of Vectibix, see the package leaflet.
Vectibix must not be used in patients who have had a severe or life-threatening hypersensitivity (allergic) reaction to panitumumab or any of the other ingredients in the past. It must not be used in patients with interstitial pneumonitis or pulmonary fibrosis (lung diseases). Vectibix must not be used with oxaliplatin-containing chemotherapy in patients whose tumour contains the mutated RAS gene or for whom the RAS status is not known.
The European Medicines Agency decided that Vectibix’s benefits are greater than its risks and it can be authorised for use in the EU.
Vectibix was originally given ‘conditional authorisation’ because there was more evidence to come about the medicine. As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vectibix have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Vectibix are continuously monitored. Side effects reported with Vectibix are carefully evaluated and any necessary action taken to protect patients.
Vectibix received a conditional marketing authorisation valid throughout the EU on 3 December 2007. This was switched to a full marketing authorisation on 15 January 2015.
Product information
Latest procedure affecting product information:
IA/0100
05/07/2022
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Vectibix
- Active substance
- panitumumab
- International non-proprietary name (INN) or common name
- panitumumab
- Therapeutic area (MeSH)
- Colorectal Neoplasms
- Anatomical therapeutic chemical (ATC) code
- L01XC08
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):
- in first-line in combination with Folfox or Folfiri.
- in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
- as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
News on Vectibix
Topics
This page was last updated on